Novo Nordisk A/S (NONOF) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Bagsvaerd, Denmark. 現CEOは Maziar Mike Doustdar.
NONOF を有する IPO日 2010-05-07, 77,406 名の正社員, に上場 Other OTC, 時価総額 $172.47B.
Novo Nordisk A/S is a global healthcare company engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company operates through two primary segments: Diabetes and Obesity Care, which includes insulins, GLP-1 therapies, oral antidiabetic products, and obesity treatments; and Biopharmaceuticals, which focuses on haemophilia, growth disorders, and hormone replacement therapy. Founded in 1923 and headquartered in Bagsvaerd, Denmark, Novo Nordisk maintains strategic collaborations with industry partners including Gilead Sciences and Lumen Bioscience to advance its pipeline in cardiometabolic disease treatments.
